

TRASTUZUMAB

BRAND NAME	HERCEPTIN, HERCEPTIN SC, HERZUMA, KANJINTI, OGIURI, ONTRUZANT, TRAZIMERA
DRUG CLASS	Non-cytotoxic antineoplastic, monoclonal antibody (humanised)
AVAILABILITY	Herceptin IV, Herzuma, Kanjinti, Ogivri, Ontruzant and Trazimera vials contain 60 mg, 150 mg or 420 mg of trastuzumab. ¹ Herceptin IV, Herzuma, Kanjinti, and Ontruzant also contain histidine hydrochloride, histidine, trehalose dihydrate and polysorbate-20. ¹ Ogivri also contains histidine hydrochloride, histidine, sorbitol and macrogol 3350. ¹ Trazimera also contains histidine hydrochloride, histidine, polysorbate-20 and sucrose. ¹ Herzuma, Kanjinti, Ogivri, Ontruzant and Trazimera are biosimilar products to Herceptin IV. Herceptin SC vial contains 600 mg/5 mL of trastuzumab. Also contains vorhyaluronidase alfa, histidine hydrochloride monohydrate, histidine, trehalose dihydrate, polysorbate-20 and methionine. ¹ The solution is clear to opalescent and colourless to yellow. ¹
WARNING	The occupational hazard of intermittent low dose exposure to trastuzumab is not known. Wear a mask and gloves when preparing the infusion solution to minimise exposure. Trastuzumab is not a cytotoxic. Severe hypersensitivity and anaphylactic reactions may occur. Resuscitation facilities must be readily available. ¹ There are IV, SUBCUT and cytotoxic (Kadcyla) formulations of trastuzumab. They are not equivalent. Check carefully to ensure the correct product is selected.
pH	IV formulations: approximately 6 when reconstituted ¹
PREPARATION	For IV use: reconstitute the 60 mg vial with 3 mL, the 150 mg vial with 7.2 mL or the 420 mg vial with 20 mL of water for injections. Swirl gently. Do not shake. Allow the vial to stand for 5 minutes. The solution is clear and colourless to slightly yellow. ¹ The concentration is approximately 21 mg/mL. ¹ Dilute the dose in 250 mL of sodium chloride 0.9%. Invert the bag gently to mix. ¹ For SUBCUT use: Herceptin SC is ready to use.
STABILITY	Vial: store at 2 to 8 °C. Do not freeze. ¹ Reconstituted solution: use immediately. ¹ Infusion solution: stable for 24 hours (Ogivri, Herzuma for 6 hours) below 30 °C or for 24 hours at 2 to 8 °C. ¹ Herceptin SC: stable in the vial or a syringe for 6 hours below 30 °C, or stable in a syringe for 24 hours at 2 to 8 °C. ¹
ADMINISTRATION	
IM injection	Not recommended ¹
SUBCUT injection	Herceptin SC only: inject over 2 to 5 minutes into the thigh. ¹
IV injection	Contraindicated ¹
IV infusion	IV formulations only: infuse the loading dose over 90 minutes. If the first dose is well tolerated, infuse subsequent infusions over 30 minutes. ¹
COMPATIBILITY	Sodium chloride 0.9% ¹
INCOMPATIBILITY	Glucose 5% ¹ , any glucose-containing fluid ¹
SPECIAL NOTES	Monitor for possible anaphylactic and infusion reactions during the infusion. ¹ Infusion reactions may be severe and include chills, fever, dyspnoea, hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation and respiratory distress. Stop the infusion and treat accordingly. Consider restarting the infusion when symptoms have settled. ¹ Anaphylactic reactions are rare but are a medical emergency. Stop the infusion and commence treatment immediately. Check your local guidelines for premedication requirements.
REFERENCES	

1. Product information. Available from www.tga.gov.au. Accessed 20/07/2021.